Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sipponen

Showing results (451-460 of 459) with videos related to

Pageof 46
Sort By:
You have reached the last page of results.This site can display upto 459 results.
Gut|January 29, 2011
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapyJean-François Rahier, Pavol Papay, Julia Salleron, et al.
European Journal of Gastroenterology & Hepatology|September 2, 2020
Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohortClas-Göran Af Björkesten, Tuire Ilus, Taru Hallinen, et al.
Autoimmunity|April 28, 2022
Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseasesTea Lamberg, Taina Sipponen, Sanna Valtanen, et al.
NEJM Evidence|February 6, 2024
Discontinuation of Infliximab Therapy in Patients with Crohn's DiseaseSine Buhl, Casper Steenholdt, Jørn Brynskov, et al.
Biologicals : Journal of the International Association of Biological Standardization|February 14, 2019
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practiceTero Ylisaukko-Oja, Saku Torvinen, Jaakko Aaltonen, et al.
Scandinavian Journal of Gastroenterology|December 21, 2017
High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)<sup></sup>Tero Ylisaukko-Oja, Jaakko Aaltonen, Heikki Nuutinen, et al.
Gut|July 18, 2000
The Vienna classification of gastrointestinal epithelial neoplasiaR J Schlemper, R H Riddell, Y Kato, et al.
American Journal of Human Genetics|February 7, 2008
Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental retardationGuy Froyen, Mark Corbett, Joke Vandewalle, et al.
Inflammatory Bowel Diseases|May 23, 2018
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European StudyUri Kopylov, Bram Verstockt, Luc Biedermann, et al.
Pageof 46

Showing results (451-460 of 459) with videos related to

Sort By:
Pageof 46
You have reached the last page of results.This site can display upto 459 results.
Gut|January 29, 2011
H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapyJean-François Rahier, Pavol Papay, Julia Salleron, et al.
European Journal of Gastroenterology & Hepatology|September 2, 2020
Objectively assessed disease activity and drug persistence during ustekinumab treatment in a nationwide real-world Crohn's disease cohortClas-Göran Af Björkesten, Tuire Ilus, Taru Hallinen, et al.
Autoimmunity|April 28, 2022
Short interruptions of TNF-inhibitor treatment can be associated with treatment failure in patients with immune-mediated diseasesTea Lamberg, Taina Sipponen, Sanna Valtanen, et al.
NEJM Evidence|February 6, 2024
Discontinuation of Infliximab Therapy in Patients with Crohn's DiseaseSine Buhl, Casper Steenholdt, Jørn Brynskov, et al.
Biologicals : Journal of the International Association of Biological Standardization|February 14, 2019
Characterization of inflammatory bowel disease management by vedolizumab and concomitant treatments in real-life clinical practiceTero Ylisaukko-Oja, Saku Torvinen, Jaakko Aaltonen, et al.
Scandinavian Journal of Gastroenterology|December 21, 2017
High treatment persistence rate and significant endoscopic healing among real-life patients treated with vedolizumab - a Finnish Nationwide Inflammatory Bowel Disease Cohort Study (FINVEDO)<sup></sup>Tero Ylisaukko-Oja, Jaakko Aaltonen, Heikki Nuutinen, et al.
Gut|July 18, 2000
The Vienna classification of gastrointestinal epithelial neoplasiaR J Schlemper, R H Riddell, Y Kato, et al.
American Journal of Human Genetics|February 7, 2008
Submicroscopic duplications of the hydroxysteroid dehydrogenase HSD17B10 and the E3 ubiquitin ligase HUWE1 are associated with mental retardationGuy Froyen, Mark Corbett, Joke Vandewalle, et al.
Inflammatory Bowel Diseases|May 23, 2018
Effectiveness and Safety of Vedolizumab in Anti-TNF-Naïve Patients With Inflammatory Bowel Disease-A Multicenter Retrospective European StudyUri Kopylov, Bram Verstockt, Luc Biedermann, et al.
Pageof 46